Following the success of Ozempic®, Wegovy®, and other GLP-1 receptor agonists, pharmaceutical companies are racing to develop the next wave of metabolic drugs. These new therapies build on the proven benefits of currently approved GLP-1s—lowering blood sugar, supporting weight loss, and reducing cardiovascular risk—while aiming for even greater results in weight management and metabolic health.
Curious about the science behind today’s most talked-about diabetes and weight-management treatments? Our new, four-part blog series on GLP-1 Agonists will break down everything you need to know — from how these drugs work, to their real-world results, side effects, and what’s coming next in the pipeline. Today, we’re covering how someone might choose between GLP-1 molecules,
Curious about the science behind today’s most talked-about diabetes and weight-management treatments? Our new, four-part blog series on GLP-1 Agonists will break down everything you need to know — from how these drugs work, to their real-world results, side effects, and what’s coming next in the pipeline. GLP-1 stands for glucagon-like peptide-1. It’s an incretin
Eli Lilly is moving closer to bringing its experimental weight loss pill, orforglipron, to market after releasing positive results from its latest phase 3 clinical trial. The study, called Attain-2, tested the once-daily pill in people who are overweight or obese and also have Type 2 diabetes—a group often harder to treat. The trial found
A major new study has found that drinking just one can of diet soda a day may raise your risk of developing type 2 diabetes by 38%. Surprisingly, this is a greater risk than what’s seen with regular sugary sodas. The study, led by researchers at Monash University, followed more than 36,000 adults aged 40
More Americans are turning to diabetes drugs like Ozempic, not for diabetes, but for weight loss. A new study shows that the use of GLP-1 medications among U.S. adults without diabetes more than tripled between 2018 and 2022. In that time, annual spending on these drugs surged from $1.6 billion to $5.8 billion. GLP-1 drugs,
In a recent randomized, controlled, double-blind trial, researchers in the United States investigated the impact of a modest daily intake of 4g of cinnamon supplements over four weeks on blood glucose levels. The study, extended with continuous glucose monitoring (CGM) and oral glucose tolerance test (OGTT) data, focused on participants with obesity and prediabetes. Contradictory
Two new phase 2 studies suggest that the investigational drug orforglipron, developed by Eli Lilly, shows promise in the treatment of obesity and type 2 diabetes. Currently, GLP-1 agonists (a class of medications utilized in the treatment of type 2 diabetes mellitus and obesity) approved for these conditions are administered via under the skin injection,
A new population-based study, involving 22 million people, shows that autoimmune disorders now affect around one in ten individuals. These conditions pose a huge burden on individuals and upon wider society, and currently represent an enormous unmet clinical need. Autoimmune diseases are a group of disorders characterized by an abnormal immune response, where the immune
Diabetes research is coming to Stouffville! This fall, Stouffville Medical Centre will host its first clinical trial for type 2 diabetes, for people who have been diagnosed within the past 4 years. JoinAStudy.ca Principal Investigator Dr. Nima Mirtorabi and the medical team in Stouffville are excited to be contributors to the next wave of diabetes
